Revolution Medicines, Inc. Income Statement

Income Statement Dec2018 Dec2019 Dec2020 Dec2021 Dec2022 Dec2023 Dec2024
Revenue & cost
Revenue 20.16M50.04M42.98M29.39M35.38M11.58M-2.53M
Gross Profit 20.16M50.04M42.98M29.39M35.38M11.58M-2.53M
Operating items
Research & Development 51.08M91.75M132.25M186.95M253.07M423.14M592.23M
Selling, General & Administrative 9.41M12.41M21.43M30.45M40.59M75.62M97.30M
Other Operating Expenses -57.15M
Operating Expenses 60.49M104.16M153.68M217.40M293.66M498.76M689.52M
Operating Income -40.33M-54.12M-110.70M-188.01M-258.28M-487.19M-689.52M
EBIT -40.33M-54.12M-110.70M-188.01M-258.28M-487.19M-689.52M
Non-operating items
Interest & Investment Income 0.78M2.19M2.24M0.93M9.15M47.48M86.88M
Non Operating Income -1.46M2.08M2.17M0.92M9.15M47.29M88.68M
Net income details
EBT -41.79M-52.04M-108.53M-187.09M-249.12M-439.89M-600.85M
Tax Provisions -4.37M-0.37M-0.42M-3.52M-0.80M
Profit After Tax -41.79M-47.66M-108.16M-187.09M-248.71M-436.37M-600.09M
Income from Continuing Operations -41.79M-47.66M-108.16M-187.09M-248.71M-436.37M-600.05M
Consolidated Net Income -41.79M-47.66M-108.16M-187.09M-248.71M-436.37M-600.05M
Income towards Parent Company -41.79M-47.66M-108.16M-187.09M-248.71M-436.37M-600.05M
Net Income towards Common Stockholders -48.82M-61.90M-110.38M-187.09M-248.71M-436.37M-600.09M
Additional items
EPS (Basic) -0.00M-0.00M-0.00M-0.00M-0.00M-0.00M-0.00M
EPS (Weighted Average and Diluted) -0.00M-0.00M-0.00M-0.00M-0.00M
Shares Outstanding (Weighted Average) 52.90M52.90M66.38M73.69M88.79M109.56M168.22M
Shares Outstanding (Diluted Average) 54.87M72.81M80.63M113.15M167.74M
EBITDA -40.33M-54.12M-110.70M-187.58M-250.11M-434.04M-599.32M
Tax Rate 8.40%0.34%0.17%0.80%0.13%